Eyewire News: The Podcast

Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world. Learn more about your ad choices. Visit megaphone.fm/adchoices

Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout of autonomous AI screening technology; and a total solar eclipse. Learn more about your ad choices....

Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices.   Learn more about your ad choices. Visit megaphone.fm/adchoices

New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoices

Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV. Learn more about your ad choices. Visit megaphone.fm/adchoices

We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development. Learn more about your ad choices. Visit megaphone.fm/adchoices

Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad choices. Visit megaphone.fm/adchoices

Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.    Learn more about your ad choices. Visit megaphone.fm/adchoices

Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system. Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona. Learn more about your ad choices. Visit megaphone.fm/adchoices

Zeiss Lenticule Extraction for Hyperopia • Alcon Ngenuity 1.5 • Oculus Pentacam Cornea OCT • Lensar ALLY Adaptive Cataract Treatment System • BVI Serenity IOLs • Topcon TRK-Omnia Learn more about your ad choices. Visit megaphone.fm/adchoices

First Therapy for Acanthamoeba Keratitis Approved in Europe • Oculus Adds Dual Testing Functionality to Easyfield VR • FDA Clears IND Application for Stem Cell Therapy for Primary Photoreceptor Diseases Learn more about your ad choices. Visit megaphone.fm/adchoices

Rayner Unveils First AI-Designed Spiral IOL • Visionix Launches VX 610 Non-Mydriatic Automated Fundus Camera • Injectsense Completes First Human Implant of Ultraminiature IOP Sensor Learn more about your ad choices. Visit megaphone.fm/adchoices

Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations • Ultrasonic Sensor Device Launched for Loss of Side Vision • Ocuvex Therapeutics Acquires Visiox Pharmaceuticals Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices

Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin • Wearable Aid with AI-Powered Visual Assistant is Unveiled • ASCRS Business of Refractive Cataract Surgery Summit Launched Learn more about your ad choices. Visit megaphone.fm/adchoices